This research topic covers areas such as
A new recommendation, based on the latest scientific evidence, to increase the number of screenings, covering more target groups and more cancers.
Scientists from the JRC and the University of Siena propose a commonly shared characterisation strategy for nanovaccines to improve performance and reduce development times.
The JRC’s status report of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM), published today, describes JRC’s contributions to several of the actions set out in the Commission’s response to the Parliament in February 2022.
One year ago, the European Commission adopted a Recommendation asking EU Member States to put in place wastewater monitoring to track COVID-19 and its variants.
The Endocrine Active Substances Information System (EASIS) is a database of studies related to chemicals that are considered to have endocrine activity.
The EURL ECVAM Search Guide provides search principles and procedures, suggested search terms and user guidance together with an inventory of...
The JRC QSAR Model Database is a database of quantitative/qualitative structure activity relationship models (QSARs) typically used for predicting...
ToxRTool provides comprehensive criteria and guidance for assessing the reliability of toxicological data.
The JRC is developing and testing new animal-free methods, alternative to animal-based tests, to be applied in an integrated safety assessment of...
The JRC is one of the major developers and producers of reference materials, which are produced in support of EU policy, for example in the areas of...
The Global Health Security Initiative is an international partnership of the G7 countries (Canada, France, Germany, Italy, Japan, the United Kingdom...
The JRC carries out research in the area of targeted alpha therapy which is a promising new approach to cancer treatment.
Good health care requires reliable measurements of health status markers, mainly in blood samples. Such In-Vitro Diagnostics measurements need to be...
